Pentosidine (Advanced Glycation End Product)Catalogue number: PEN012
|Product Type||Primary Antibodies|
This antibody is suitable for the detection of bound and free pentosidine in tissues and tissue extracts. Long-term incubation of proteins with glucose leads, through Schiff's base and Amadori rearrangement products, to the formation of advanced glycation end products (AGE) which are characterized by fluorescence, brown color and inter- and intra-molecular cross-linking. Recent immunological studies using anti-AGE antibodies demonstrated the presence of AGE in (i) human lens, (ii) renal proximal tubules in patients with diabetic nephropathy and chronic renal failure, (iii) atherosclerotic lesions of arterial walls, (iv) ß2-microglobulin of carpal tunnel amyloid fibril deposits in patients with hemodialysis-related amyloidosis and (v) brain tissues of patients with Alzheimer’s disease. Pentosidine is one of the Maillard products, which were detected by Sell and Monnier (1989). Pentosidines have been shown to cross-link Arginine and Lysine residues. They were found in ß2-microglobulin of patients suffering from hemodialysis-related amyloidosis (Miyata et al., 1996). Reacts with pentosidine-HSA and free pentosidine in competitive ELISA.
Protein G affinity purified antibody from ascites in stabilized buffer, containing 50% Block Ace (Casein-containing solution, Dainippon Co.) and 0.1% ProClin (Rohm & Haas) as a preservative
Purification Method: Protein G affinity purified antibody from ascites in stabilized buffer, containing 50% Block Ace? (Casein-containing solution, Dainippon Co.) and 0.1% ProClin? (Rohm & Haas) as a preservative
Concentration: 0.25 mg/ml
Secondary Reagents: We recommend the use of BIOLOGO's Universal Staining System DAB (Art. No. DA005) or AEC (Art. No. AE005).
Species Reactivity: not relevant
Incubation Time: 60 min at RT or 18 hr at 2-8°C
Working Concentration: (liquid conc.) ELISA 0.1-0.5 µg/ml; IHC 2 µg/ml
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations.This datasheet is as accurate as reasonably achievable, but Exalpha Biologicals accepts no liability for any inaccuracies or omissions in this information.
1. Horiuchi S., Araki N., and Morino Y. (1991) Immunological approach to characterize advanced glycation end products of the Maillard reaction: Evidence for the presence of a common stucture. J. Biol. Chem. 266; 7329-7332. 2. Sell D.R. and Monnier V.M.(1989) : Structure Elucidation of a Senescence Cross-link from Human Extracellular Matrix. Implication of pentoses in aging process. J.Biol.Chem.264 : 21597-21602 3. Miyata T, Taneda S., Kawai R., Ueda Y., Horiuchi S., Hara M., Maeda K., and Monnier V.M. (1996) : Identification of pentosidine as a native structure for advanced glycation end products in ?2-microglobulin-containing amyloid fibrils in patients with dialysis-related amyloidosis. Proc.Natl.Acad.Sci.USA 93 : 2353-2358
Pentosidine (Advanced Glycation End Product)